Parkinson's disease
Conditions
Interventions
A:phase I: levodopa/carbidopa
phase II: levodopa/benserazide
B:phase I: levodopa/benserazide
phase II: levodopa/carbidopa
Sponsors
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
Eligibility
Sex/Gender
All
Age
30 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Primary PD patients (diagnosed according to the 2015 MDS diagnostic criteria); 2. Long-term use of anti-PD drugs; 3. Hoehn and Yahr [H&Y] stage > or = 3; 4. Men and women with aged 30-85 years;5.Inform consent form.
Exclusion criteria
Exclusion criteria: 1. Hoehn and Yahr [H&Y] stage < 3; 2. Serious impairment of liver, kidney, heart and lung function; 3. Severe anemia; 4. Deep brain stimulation history; 5. Disease that is considered to interfere with research (Such as diarrhea and/or gastrointestinal malabsorption); 6. Allergic to any of the experimental drugs; 7. Demented PD; Pregnant woman; 8. Women who are pregnant or breastfeeding; 9. Alcohol or drug dependence; 10. Patients are participating in other clinical studies or have participated in other clinical studies in the previous 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Levodopa plasma concentration;Carbidopa plasma concentration;Benserazide plasma concentration;MDS-UPDRS III;Dopamine plasma concentration; | — |
Countries
China
Contacts
Public ContactWeiguo Liu
The Fourth Affiliated Hospital of Nanjing Medical University
Outcome results
None listed